Information Provided By:
Fly News Breaks for March 4, 2020
Mar 4, 2020 | 08:49 EDT
Wells Fargo analyst Jim Birchenough raised the firm's price target on Gilead (GILD) to $87 from $81 and keeps an Overweight rating on the shares following recent outperformance and on assessment of potential remdesivir opportunity in addressing current coronavirus outbreak. Overall, the analyst believes incremental value can be justified, and see further upside potential on broader pipeline progress, new opportunity with Forty Seven (FTSV) acquisition and potential for additional deals.
News For GILD;FTSV From the Last 2 Days
Jun 1, 2020 | 16:36 EDT
Specialty Pharma Analysts Chen & Kim and Biopharma Analyst Folkes discuss the unment needs in the treatment of Type 2 Diabetes, NASH and Obesity, Novo's Rybelsus usage, Eli Lilly's Trulicity and Tirzepatide and a review of NASH treatments in development from Gilead, Novo, Intercept and CymaBay on an Analyst/Industry conference call to be held on June 5 at 11 am.
Jun 1, 2020 | 11:58 EDT
Stocks are extending their recent rally despite an increasing number of U. S... To see the rest of the story go to See Story Here
Jun 1, 2020 | 08:53 EDT
Gilead Sciences shares are down $1.60, or 2%, to $76.23 in pre-market trading after the company announced earlier topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia.